Biologics litigation is evolving beyond classic biosimilar disputes, driven by higher-value products, an uptake in branded-vs-branded disputes, and growing injunction risk. This session brings together leading litigators and in-house counsel to examine how strategy is changing.
- How biologics disputes are starting earlier and outside traditional biosimilar timelines, (e.g. Novo Nordisk v. Eli Lilly), and what this means for launch and portfolio strategy.
- Examine the rise of branded-vs-branded cases like Alnylam Pharmaceuticals, Inc. v. Moderna, Inc., and how innovator enforcement and defence strategies are adapting.
- Review recent BPCIA cases and outcomes, including Hikma/Richter v. Amgen.
- Consider parallel proceedings in Europe and other jurisdictions and examine how they’re increasingly shaping U.S. biologics litigation decisions.
Alex Gloor
Nicole Clouse
Katie Nolan Stevaux
Arshad Jamil
Arshad Jamil is a senior Patent Attorney with extensive experience of more than 2 decades in the legal and IP rights fields. Arshad is the Chief IP counsel and Global head of IP rights at Biocon Biologics, where he is responsible for devising IP strategy and handling Global Patent litigation for Biosimilars and the Biocon Group’s patent and trademark filings and policy. Arshad manages Biocon group of companies IP portfolio of 1100+ global patents and 950+ global trademarks.
In his previous assignment, Arshad was a Senior Patent Attorney at Sun Pharma, where he handled ANDA litigations, including Hatch Waxman settlements. Arshad is an Engineer turned lawyer and have Bachelor of engineering (B.E.), Bachelor of Laws(LL.B.) and executive MBA degrees to his credit. Arshad is a distinguished speaker at National /International IP forums and recognised by IAM as The World’s leading IP strategists consecutively for 5 years 2017 , 2018, 2019, and 2020 and 2021 editions of IAM strategy 300.